Growth Metrics

Edwards Lifesciences (EW) Short term Debt (2017 - 2018)

Edwards Lifesciences has reported Short term Debt over the past 7 years, most recently at $599.2 million for Q2 2018.

  • Quarterly results put Short term Debt at $599.2 million for Q2 2018, changed N/A from a year ago — trailing twelve months through Jun 2018 was $599.2 million (changed N/A YoY), and the annual figure for FY2017 was $598.0 million, changed.
  • Short term Debt for Q2 2018 was $599.2 million at Edwards Lifesciences, roughly flat from $598.6 million in the prior quarter.
  • Over the last five years, Short term Debt for EW hit a ceiling of $599.2 million in Q2 2018 and a floor of $2.2 million in Q3 2014.
  • Median Short term Debt over the past 3 years was $319.8 million (2017), compared with a mean of $307.0 million.
  • Peak annual rise in Short term Debt hit 80.15% in 2014, while the deepest fall reached 80.15% in 2014.
  • Edwards Lifesciences' Short term Debt stood at $2.6 million in 2014, then surged by 22900.0% to $598.0 million in 2017, then grew by 0.2% to $599.2 million in 2018.
  • The last three reported values for Short term Debt were $599.2 million (Q2 2018), $598.6 million (Q1 2018), and $598.0 million (Q4 2017) per Business Quant data.